✦ LIBER ✦

High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias

✍ Scribed by M. C. Petti; A. Tafuri; R. Latagliata; M. A. Aloe Spiriti; E. Montefusco; M. Mancini; G. Meloni; M. T. Petrucci; A. Spadea; R. Redi; G. Alimena; F. Mandelli

Book ID: 105988252
Publisher: Springer
Year: 2003
Tongue: English
Weight: 130 KB
Volume: 82
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-003-0693-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute myeloid leukemia in t

Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol

✍ Christopher A. Slapak; Jane F. Desforges; Terry Fogaren; Dr. Kenneth B. Miller 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

All-transretinoic acid plus low doses of

All-transretinoic acid plus low doses of cytarabine for the treatment of “poor-risk” acute myeloid leukemias

✍ A. Venditti; R. Stasi; M. Masi; G. Del Poeta; C. Cox; A. Franchi; D. Piccioni; A 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 163 KB

Toxicity of sequential high-dose ARA-C a

Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia

✍ Gr�mayer, Eva Renate ;Schmidmeier, Waltraud ;Panzer, Simon ;Gadner, Helmut 📂 Article 📅 1986 🏛 Springer-Verlag ⚖ 347 KB

High-dose cytosine arabinoside and idaru

High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis

✍ Steven Barone; Maria R. Baer; Sheila N.J. Sait; David Lawrence; AnneMarie W. Blo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 2 views

Evolving treatment strategies in patient

Evolving treatment strategies in patients with high-risk acute myeloid leukemia

✍ Schiller, Gary J. 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 169 KB

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer